* Loxo Oncology Announces First Pediatric Response to
LOXO-101, it induces 90 percent tumor regression in toddler with
refractory infantile fibrosarcoma
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
No comments:
Post a Comment